CSIMarket
 


Atyr Pharma Inc  (LIFE)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare

Atyr Pharma Inc's Working Capital Ratio

LIFE's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




LIFE Working Capital Ratio (Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
Y / Y Current Liabilities Change -57.39 % -54.62 % -32.08 % -13.31 % -6.53 %
Y / Y Current Assets Change 3.49 % 11.3 % -2.37 % -0.07 % 12.58 %
Working Capital Ratio MRQ 11.71 6.06 4.76 4.47 4.82
Overall Ranking # # # # #
Seq. Current Liabilities Change -24.1 % -27 % -18.02 % -6.18 % -19.18 %
Seq. Current Assets Change 46.73 % -7.03 % -12.82 % -12.97 % 57.79 %



Working Capital Ratio first quarter 2021 Comment
Atyr Pharma Inc's Current Assets grew by 46.73 % in I. Quarter sequntially, while Current Liabilities decreased, this led to improvement in Atyr Pharma Inc's Working Capital Ratio to 11.71, Working Capital Ratio remained below Atyr Pharma Inc average.

Within Biotechnology & Drugs industry 61 other companies have achieved higher Working Capital Ratio than Atyr Pharma Inc in first quarter 2021. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is LIFE most successful ?
Working Capital Ratio LIFE on the trailing twelve month basis
Working Capital Ratio first quarter 2021 Company Ranking
Within: No.
Biotechnology & Drugs Industry # 62
Healthcare Sector # 225
Overall Market # 553


Working Capital Ratio Statistics
High Average Low
12.69 4.04 0.98
(Sep 30 2015)   (Dec 31 2012)




Financial Statements
Atyr Pharma Inc's Current Liabilities $ 4 Millions Visit LIFE's Balance sheet
Atyr Pharma Inc's Current Assets $ 52 Millions Visit LIFE's Balance sheet
Source of LIFE's Sales Visit LIFE's Sales by Geography




Companies with similar Working Capital Ratio in the quarter endingMar 31 2021, within Biotechnology & Drugs Industry Working Capital RatioMar 31 2021 MRQ Current AssetsMar 31 2021 MRQ Current Liabilities
Assembly Biosciences inc   30.69 $ 221.634  Millions$ 7.221  Millions
Iteos Therapeutics Inc   27.47 $ 324.919  Millions$ 11.830  Millions
Solid Biosciences Inc   27.46 $ 274.295  Millions$ 9.988  Millions
Protara Therapeutics Inc   27.23 $ 87.697  Millions$ 3.221  Millions
Cocrystal Pharma Inc   26.87 $ 33.691  Millions$ 1.254  Millions
Vitality Biopharma Inc   26.54 $ 0.887  Millions$ 0.033  Millions
Denali Therapeutics Inc   26.22 $ 1,431.622  Millions$ 54.610  Millions
Satsuma Pharmaceuticals Inc   25.50 $ 136.414  Millions$ 5.349  Millions
Curis Inc   25.36 $ 161.862  Millions$ 6.382  Millions
Arca Biopharma Inc   23.86 $ 68.730  Millions$ 2.880  Millions
Rubius Therapeutics inc   23.71 $ 336.258  Millions$ 14.185  Millions
Aptose Biosciences Inc   23.59 $ 114.144  Millions$ 4.839  Millions
89bio Inc   23.40 $ 197.936  Millions$ 8.459  Millions
Igm Biosciences Inc   23.02 $ 341.177  Millions$ 14.818  Millions
Diffusion Pharmaceuticals Inc   22.39 $ 47.314  Millions$ 2.113  Millions
Salarius Pharmaceuticals inc   22.27 $ 41.651  Millions$ 1.871  Millions
Crispr Therapeutics Ag  22.05 $ 1,832.359  Millions$ 83.090  Millions
Allovir Inc   21.91 $ 339.664  Millions$ 15.500  Millions
Immunovant Inc   21.79 $ 409.006  Millions$ 18.771  Millions
Jounce Therapeutics inc   20.66 $ 267.013  Millions$ 12.925  Millions
Forma Therapeutics Holdings Inc   20.65 $ 654.447  Millions$ 31.700  Millions
Adverum Biotechnologies Inc   20.57 $ 409.855  Millions$ 19.923  Millions
Oncternal Therapeutics Inc   20.38 $ 113.084  Millions$ 5.550  Millions
Aerpio Pharmaceuticals Inc   19.62 $ 40.999  Millions$ 2.090  Millions
4d Molecular Therapeutics Inc   19.01 $ 264.501  Millions$ 13.916  Millions
Tarsus Pharmaceuticals Inc   18.92 $ 191.451  Millions$ 10.118  Millions
Kymera Therapeutics Inc   17.77 $ 340.791  Millions$ 19.177  Millions
Palisade Bio Inc   17.72 $ 8.756  Millions$ 0.494  Millions
Dyadic International Inc  15.98 $ 27.991  Millions$ 1.751  Millions
Revolution Medicines Inc   15.94 $ 697.405  Millions$ 43.759  Millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PRPL's Profile

Stock Price

PRPL's Financials

Business Description

Fundamentals

Charts & Quotes

PRPL's News

Suppliers

PRPL's Competitors

Customers & Markets

Economic Indicators

PRPL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071